An Open-Label, Multicenter, Phase Ib Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290, A Fibroblast Activation Protein-A (FAP) Targeted 4-1BB Ligand (CD137L), In Combination With Cibisatamab With Obinutuzumab Pre-Treatment, In Participants With Previously Treated, Metastatic, Microsatellite-stable Colorectal Adenocarcinoma With High CEACAM5 Expression

This is an open-label, multicenter, Phase Ib study to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) in the weekly (QW) and/or every 3 weeks (Q3W) regimens, safety, tolerability, PK, immunogenicity, PD profile and to evaluate preliminary anti-tumor activity of RO7122290 in combination with cibisatamab Q3W after pretreatment with obinutuzumab, in participants with previously treated metastatic, microsatellite-stable colorectal adenocarcinoma with high CEACAM5 expression

开始日期2021-07-14

申办/合作机构

Hoffmann-La Roche, Inc.

NCT03866239

/ Terminated临床1期

A Phase Ib, Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Patients With Previously Treated Metastatic, Microsatellite-Stable Colorectal Adenocarcinoma With High CEACAM5 Expression

CO40939 is a Phase Ib, open-label, multicenter, single-arm study designed to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of cibisatamab in combination with atezolizumab administered after pretreatment with obinutuzumab in patients with Stage IV microsatellite stable (MSS) metastatic colorectal cancer (mCRC) whose tumors have high carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expression and who have progressed on two or more chemotherapy regimens. The study is composed of a safety run-in and an exploratory part.

开始日期2019-05-07

申办/合作机构

Hoffmann-La Roche, Inc.

NCT03337698

/ Active, not recruiting临床1/2期

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)

This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in participants with metastatic non-small cell lung cancer (NSCLC).
Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of participants with tumor PD-L1 expression who have received no prior systemic therapy for metastatic NSCLC, and Cohort 2 will consist of participants who experienced disease progression during or following treatment with a platinum-containing regimen and a PD-L1/PD-1 checkpoint inhibitor, given in combination as one line of therapy or as two separate lines of therapy, regardless of PD-L1 expression. In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). Participants who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment regimen (Stage 2).

开始日期2018-01-02

申办/合作机构

Hoffmann-La Roche, Inc.

100 项与 Cibisatamab 相关的临床结果

登录后查看更多信息

100 项与 Cibisatamab 相关的转化医学

登录后查看更多信息

100 项与 Cibisatamab 相关的专利（医药）

登录后查看更多信息

510

项与 Cibisatamab 相关的文献（医药）

2024-09-01·INTERNATIONAL IMMUNOPHARMACOLOGY

Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors

Review

作者: Zhu, Jianwei ; Liu, Junjun

T-cell-engaging bispecific antibody (TCB) therapies have emerged as a promising immunotherapeutic approach, effectively redirecting effector T cells to selectively eliminate tumor cells. The therapeutic potential of TCBs has been well recognized, particularly with the approval of multiple TCBs in recent years for the treatment of hematologic malignancies as well as some solid tumors. However, TCBs encounter multiple challenges in treating solid tumors, such as on-target off-tumor toxicity, cytokine release syndrome (CRS), and T cell dysfunction within the immunosuppressive tumor microenvironment, all of which may impact their therapeutic efficacy. In this review, we summarize clinical data on TCBs for solid tumor treatment, highlight the challenges faced, and discuss potential solutions based on emerging strategies from current clinical and preclinical research. These solutions include TCB structural optimization, target selection, and combination strategies. This comprehensive analysis aims to guide the development of TCBs from design to clinical application, addressing the evolving landscape of cancer immunotherapy.

2024-07-02·Molecular cancer therapeutics

Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer

Article

作者: Dakhel Plaza, Sheila ; Halin, Cornelia ; Oxenius, Annette ; Puca, Emanuele ; Pellegrino, Christian ; Rotta, Giulia ; Nideroest, Larissa ; De Luca, Roberto ; Thoma, Marina ; Peissert, Frederik ; Manz, Markus G. ; Plüss, Louis ; Neri, Dario ; Pfister, Stefanie K. ; Zangger, Nathan ; Elsayed, Abdullah

Abstract:

Metastatic colorectal cancer remains a leading cause of cancer-related deaths, with a 5-year survival rate of only 15%. T cell–engaging bispecific antibodies (TCBs) represent a class of biopharmaceuticals that redirect cytotoxic T cells toward tumor cells, thereby turning immunologically “cold” tumors into “hot” ones. The carcinoembryonic antigen (CEA) is an attractive tumor-associated antigen that is overexpressed in more than 98% of patients with colorectal cancer. In this study, we report the comparison of four different TCB formats employing the antibodies F4 (targeting human CEA) and 2C11 (targeting mouse CD3ε). These formats include both antibody fragment–based and IgG-based constructs, with either one or two binding specificities of the respective antibodies. The 2 + 1 arrangement, using an anti-CEA single-chain diabody fused to an anti-CD3 single-chain variable fragment, emerged as the most potent design, showing tumor killing at subnanomolar concentrations across three different CEA+ cell lines. The in vitro activity was three times greater in C57BL/6 mouse colon adenocarcinoma cells (MC38) expressing high levels of CEA compared with those expressing low levels, highlighting the impact of CEA density in this assay. The optimal TCB candidate was tested in two different immunocompetent mouse models of colorectal cancer and showed tumor growth retardation. Ex vivo analysis of tumor infiltrates showed an increase in CD4+ and CD8+ T cells upon TCB treatment. This study suggests that bivalent tumor targeting, monovalent T-cell targeting, and a short spatial separation are promising characteristics for CEA-targeting TCBs.

2024-07-01·The journal of trauma and acute care surgery

Is barbed better? Evaluation of triclosan-coated barbed suture on wound complications following emergency laparotomy

Article

作者: Schellenberg, Morgan ; Park, Stephen ; Gallagher, Shea ; Martin, Matthew J ; Matsushima, Kazuhide ; Inaba, Kenji ; McGillen, Patrick ; Dilday, Joshua ; Lee, Heewon

INTRODUCTION:

Emergent laparotomy is associated with significant wound complications including surgical site infections (SSIs) and fascial dehiscence. Triclosan-coated barbed (TCB) suture for fascial closure has been shown to reduce local complications but primarily in elective settings. We sought to evaluate the effect of TCB emergency laparotomy fascial closure on major wound complications.

METHODS:

Adult patients undergoing emergency laparotomy were prospectively evaluated over 1 year. Patients were grouped into TCB versus polydioxanone (PDS) for fascial closure. Subanalysis was performed on patients undergoing single-stage laparotomy. Primary outcomes were SSI and fascial dehiscence. Multivariate analysis identified independent factors associated with SSI and fascial dehiscence.

RESULTS:

Of the 206 laparotomies, 73 (35%) were closed with TCB, and 133 (65%) were closed with PDS. Trauma was the reason for laparotomy in 73% of cases; damage-control laparotomy was performed in 27% of cases. The overall rate of SSI and fascial dehiscence was 18% and 10%, respectively. Operative strategy was similar between groups, including damage-control laparotomy, wound vac use, skin closure, and blood products. Surgical site infection events trended lower with TCB versus PDS closure (11% vs. 21%, p = 0.07), and fascial dehiscence was significantly lower with TCB versus PDS (4% vs. 14%, p < 0.05). Subanalysis of trauma and nontrauma cases showed no difference in SSI or fascial dehiscence. Multivariable analysis found that TCB decreased the likelihood of fascial dehiscence (odds ratio, 0.07; p < 0.05) following emergency laparotomy. Increased odds of fascial dehiscence were seen in damage-control laparotomy (odds ratio, 3.1; p < 0.05).

CONCLUSION:

Emergency laparotomy fascial closure with TCB showed significantly decreased rates of fascial dehiscence compared with closure with PDS and a strong trend toward lower SSI events. Triclosan-coated barbed suture was independently associated with decreased fascial dehiscence rates after emergency laparotomy.

LEVEL OF EVIDENCE:

Therapeutic/Care Management; Level III.

项与 Cibisatamab 相关的新闻（医药）

2024-03-20

·GlobeNewswire-Health Care

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX - - Program is one of several ongoing collaboration projects in broad CytomX-Astellas alliance on T-cell engaging bispecifics - - CytomX retains option for US co-commercialization and economic rights for certain programs - March 18, 2024 -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that the first clinical candidate in its TCB agreement with Astellas has entered into GLP toxicology studies which triggers a $5 million payment to CytomX. The clinical candidate is the first PROBODY® TCB molecule under this alliance to progress into a GLP toxicology study. CytomX and Astellas are also collaborating on additional conditionally activated TCB programs with CytomX eligible to receive future preclinical, clinical and commercial milestones. CytomX retains a cost share and co-commercialization option on a select number of targets. “We are excited by the continued momentum towards a potential future IND for the first PROBODY® TCB clinical candidate in our collaboration with Astellas, and we continue to partner with Astellas on multiple preclinical programs. The progress with this collaboration highlights the benefits of our strategy to create value through both wholly-owned and partnered programs, as well as the potential of our expanding pipeline of PROBODY T-cell engagers which are designed to localize T-cell activity to the tumor microenvironment,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics. CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engagers, and immune modulators such as cytokines. CytomX’s clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule, EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers. CX-801 is an interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter). The content above comes from the network. if any infringement, please contact us to modify.

引进/卖出

2024-01-06

·佰傲谷BioValley

第二代4-1BB激动剂的两条路

4-1BB（CD137，TNFRSF9）是T细胞上的重要共刺激受体（4-1BB/CD137，走过25年的风雨...），1989年被发现，1997年BMS的科学家在Nature Medicine发文：4-1BB单克隆抗体能够诱导改善的抗肿瘤T细胞活化，从而根除小鼠模型肿瘤。之后，BMS开发了4-1BB激动型抗体urelumab，但是有明显的肝毒性。第一代4-1BB激动剂第一代4-1BB激动剂有两个代表：urelumab（BMS-663513）和utomilumab（PF-05082566）。4-1BB抗体激动剂临床开发始于2005年，urelumab（BMS-663513）用于治疗晚期癌症（NCT00309023）。初步结果很有希望，但发生了两起肝毒性引起的死亡的不良事件。随后，当以安全剂量（0.1mg / kg）治疗，疗效有限。第二个4-1BB激动抗体utomilumab（PF-05082566），于2011年进入临床（NCT01307267）。与urelumab不同，utomilumab没有诱导重大毒性，但疗效非常有限，即使联用利妥昔也是如此，最终停止开发。第二代4-1BB激动剂两条路首要问题，需要搞明白4-1BB的定位：共刺激分子(免疫调节剂），起辅助角色。单药使用，安全剂量下，4-1BB激动剂不足以充分激活T细胞等。加大剂量，需要面临肝毒性的风险。和强力药物联合使用或者做成双特异/多特异性抗体是第二代4-1BB激动剂的两条路。CD137/4-1BB联合用药（Cancer Discov 2023）1.联合疗法虽然4-1BB表达与实体瘤中抗肿瘤CD8 + TIL的功能呈正相关，但T细胞上的4-1BB表达是多种多样的，且是动态变化的。为了充分发挥4-1BB激动剂作用，联合促进4-1BB表达的疗法是理想状态。联合免疫检查点抑制剂（最多的联用）在临床前研究中，PD1 / PD-L1抑制与4-1BB激动剂的组合显示出协同作用。因此，曾经临床试验中，有12种4-1BB激动剂联合使用PD-(L)1抑制剂。通过受体占用率优化以实现最佳MoA。如图所示，~50%的PD-L1受体占用率将导致最大的4-1BB激动作用，而在PD-L1受体占用率接近100%时，将达到最佳的PDL1抑制。然而，PD-L1的100%受体占有率会降低基于钟形曲线假说的4-1BB活化。因此，与非竞争性 PD-1 或 PD-L1 抑制剂的额外联合使用可能是有益的。Gen1046/BNT311和INBRX-105/ES101，PD-L1和4-1BB双特异性抗体，都与PD-1阻断抗体pembrolizumab联合。除免疫检查点抑制剂外，罗氏RO7227166(CD19X4-1BB)选择联用Cibisatamab(CEAXCD3) 或抗CD20 单抗 Obinutuzumab（奥妥珠单抗，商品名 Gazyva），治疗B细胞非霍奇金淋巴瘤。礼进生物LVGN6051 联用VEGFR抑制剂Anlotinib。2.双/三/四特异性4-1BB激动剂另一组第二代4-1BB激动剂是双特异性、三特异性或四特异性4-1BB激动剂。4-1BB抗体是其中一臂，第二靶点多样，包括肿瘤细胞表面分子（HER2，PSMA，EGFRvIII，Claudin18.2，ROR1，Nectin-4，CD47，CD19等），肿瘤基质和肿瘤浸润淋巴结表面分子（如FAP），肿瘤细胞和抗原呈递细胞表面分子（如PD-L1），仅在免疫细胞上表达的分子（CD40，OX40，CD3）。4-1BB是双特异性抗体排名第6的靶点，非T细胞衔接器双抗排名第1位，与PD-L1搭档。Acta Pharm Sin B. 2023小结在过去的5年中，对第二代4-1BB激动剂的研究已经大大扩展，克服第一代4-1BB激动剂的缺陷，实现安全有效的 4-1BB 超聚集。到目前为止，所有4-1BB激动剂都显示出良好的安全性和耐受性，并且具有可控的irAEs。但是有效性仍待时间证明。进行中的4-1BB激动剂临床试验NCT#Study TitleNCT05159388A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid TumorsNCT05117242Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung CancerNCT04144842Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017NCT033643484-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast CancerNCT04826003Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-TreatmentNCT05523947Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid TumorNCT05564806Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin LymphomaNCT03330561PRS-343 in HER2-Positive Solid TumorsNCT05301764A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue SarcomaNCT04740424FS222 First in Human Study in Patients With Advanced MalignanciesNCT04121676Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced CancerNCT05360381HLX35(EGFR/4-1BB Bispecific) in Patients With Advanced or Metastatic Solid TumorsNCT04648202FS120 First in Human Study in Patients With Advanced MalignanciesNCT05614258Study of ADG206 in Subjects With Advanced/Metastatic Solid TumorsNCT04077723A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaNCT05040932Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic MalignancyNCT04762641This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects With Any Progressive Locally Advanced or Metastatic Solid TumorsNCT03809624Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer参考文献Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellström KE, Mittler RS, Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3(682–685):682–85Ignacio Melero et al,CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary，Cancer Discov 2023;13:552–69Neil H Segal et al, Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody,Clin Cancer Res. 2017 Apr 15;23(8):1929-1936Sun Y, Yu X, Wang X, Yuan K, Wang G, Hu L, Zhang G, Pei W, Wang L, Sun C, Yang P. Bispecific antibodies in cancer therapy: Target selection and regulatory requirements. Acta Pharm Sin B. 2023 Sep;13(9):3583–97. doi: 10.1016/j.apsb.2023.05.023. Epub 2023 May 23. PMCID: PMC10501874.本周好文推荐如需转载请联系佰傲谷并在醒目位置注明出处﹀ ···

免疫疗法临床结果临床终止

2023-11-18

·蒲公英Ouryao

扛不住了！武田也砍掉四个管线！

转自：蒲公英Ouryao 整理：蒿山君近日，武田制药公布了上半年数据，砍掉了4条管线，业绩预期下调了高达71%。财报显示增长遇到一定的瓶颈。武田砍掉了4条管线2023年武田上半年总销售约138.71亿美元，同比增长1.4%，但利润却大幅下滑，下降了53%，约为17.87亿美元。武田产品管线可以分为五大部分，分别是：消化道产品、罕见病、血浆制品、精神疾病和抗肿瘤线。其中，消化道产品是他们的核心管线，上半年实现同比增长9.2%，报告显示，由于一系列不可控因素，导致了公司的净亏损增长，并且宣布砍掉4款研发产品管线，分别是： 1.Exkivity：治疗晚期非小细胞肺癌的产品，因III期临床试验无疗效获益而终止。 2.TAK-920/DNL-919：治疗AD类产品，因出现"中度、可逆的血液学效应"，停止了阿尔茨海默氏症（AD）药物的开发。 3.TAK-611：显示在在治疗异染性脑白质营养不良（MLD）的II期试验中未达到主要终点和次要终点而放弃研发。 4.TAK-105：由于数据表现不佳，治疗恶心和呕吐的候选药物TAK-105将停止研发。一款新药的问世绝非易事，面对新药研发困难、销售业绩下滑等压力冲击，药企巨头也不得不做出管线调整的决定，看看各大外企每年在研发领域的投入以及每年宣布放弃的产品线就可想而知。多家药企砍管线辉瑞砍5条管线：10月31日，第三季度财报的同一天，辉瑞宣布将削减5项临床项目，包括两个II期项目和三个I期项目，涉及癌症和皮肤病等领域。GSK砍3条管线：11月1日，公司财报显示，对其一期肿瘤项目进行了两项削减，中止了一个LAG-3靶向抗体和一个小分子STING激动剂-后者被称为GSK3745417。葛兰素史克还放弃了一个重组蛋白项目，该项目正处于治疗艰难梭菌的一期开发阶段。今年，GSK还结束对细胞基因疗法领域的投入。罗氏又砍掉4条管线：罗氏在近期公布的第三季度最新财报中透露，基于“全部疗效和安全性数据以及治疗领域不断变化的治疗格局”，放弃cibisatamab的实体瘤I期试验，Cibisatamab是一种与癌胚抗原结合的T细胞双特异性抗体。因在TWAINI试验中的无效性分析失败，在TWAINII试验中也没有达到主要终点，放弃治疗精神分裂症的TAAR1激动剂ralmitaront的II期项目。因在对中重度至重度非增殖性糖尿病视网膜病变患者进行的CANBERRAII期研究中，未能达到主要终点，放弃了治疗糖尿病视网膜病变的vicasinabin的II期项目。因上个月的III期试验结果不及预期，罗氏还放弃了其BCL-2抑制剂Venclexta联合地塞米松治疗复发或难治性多发性骨髓瘤的研究，但Venclexta联合阿扎胞苷治疗一线骨髓增生异常综合征的III期试验仍在进行中。值得注意的是，罗氏在一季度砍掉6条管线，半年报中提到，将终止几款候选药物开发，包括处于III期阶段的替奈普酶治疗卒中适应症，II期阶段血友病A基因疗法RG6358，以及4款尚处于I期研究阶段的新分子实体药物。艾伯维，删除2条管线：8月23日，艾伯维更新了管线，从其产品线中删除了2条ADC管线，包括ABBV-011和与辉瑞合作的ABBV-647。百时美施贵宝，削减6个项目：9月14日，百时美施贵宝在其研发日公布削减研发管线，包括两个2期临床项目（HSP47和一个TIGIT实体瘤项目）和四个1期临床项目。 Moderna，删减4个管线：靠新冠疫苗暴富的Moderna，其将“在需要时”进行管道优先排序而剔除。其中包括两个阿斯利康合作后放弃的管线AZD8601、MEDI1191以及mRNA-1653、mRNA-1703。另外，今年以来，赛诺菲结束了BTK抑制剂atuzabrutinib的开发，停止度普利尤单抗的过敏性真菌性鼻炎和无鼻息肉的慢性鼻窦炎两个项目；诺华则砍去了在研管线中10%的非核心项目等。参考：公司财报华夏日报

财报基因疗法临床3期临床1期

100 项与 Cibisatamab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11489	-	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性结直肠癌	临床2期	丹麦	Hoffmann-La Roche, Inc.	2021-07-14
转移性结直肠癌	临床2期	荷兰	Hoffmann-La Roche, Inc.	2021-07-14
转移性结直肠癌	临床2期	韩国	Hoffmann-La Roche, Inc.	2021-07-14
转移性结直肠癌	临床2期	西班牙	Hoffmann-La Roche, Inc.	2021-07-14
转移性结直肠癌	临床2期	英国	Hoffmann-La Roche, Inc.	2021-07-14
转移性微卫星稳定结直肠癌	临床2期	丹麦	Hoffmann-La Roche, Inc.	2021-07-14
转移性微卫星稳定结直肠癌	临床2期	荷兰	Hoffmann-La Roche, Inc.	2021-07-14
转移性微卫星稳定结直肠癌	临床2期	韩国	Hoffmann-La Roche, Inc.	2021-07-14
转移性微卫星稳定结直肠癌	临床2期	西班牙	Hoffmann-La Roche, Inc.	2021-07-14
转移性微卫星稳定结直肠癌	临床2期	英国	Hoffmann-La Roche, Inc.	2021-07-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02324257 (ESMO2017) 人工标引	临床1期	结肠转移性腺癌 CEA Positive	45	RG7802 (CRC and At doses ≥ 60 mg)	蓋衊襯醖窪憲壓遞網憲(範齋膚網淵餘襯製齋簾) = In S1 (out of 59 pts > 40 mg), IRRs (24%) and diarrhea (7%). 願醖顧鏇餘窪壓築艱襯 (餘鹽範網鬱餘糧艱蓋襯 ) 更多	积极	2017-09-11
				Atezolizumab+RG7802 (CRC and At doses ≥ 60 mg)
NCT02324257 \| NCT02650713 (ASCO2017)	临床1期	转移性结直肠癌	-	CEA-CD3 TCB	構憲鏇糧廠鏇觸遞網獵(鹽顧範衊鹹願鏇觸憲獵) = 膚鹹糧餘積繭鏇製鹽廠窪鑰構窪夢鏇遞鑰壓膚 (鹹蓋廠壓膚觸顧築選齋 ) 更多	-	2017-05-30
				Atezolizumab	構憲鏇糧廠鏇觸遞網獵(鹽顧範衊鹹願鏇觸憲獵) = 鑰鹹膚製遞廠餘鹽鹽構窪鑰構窪夢鏇遞鑰壓膚 (鹹蓋廠壓膚觸顧築選齋 )